Keywords: promising, mid-stage, data, apixaban, acs, drug, majors

Promising mid-stage data on apixaban in ACS

Article | 08 September 2008

Print This

US drug majors Bristol-Myers Squibb and Pfizer have reported encouraging results from APPRAISE-1, a Phase II dose-ranging study testing their ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in